Pharming Group (PHAR) said Thursday it expects 2025 revenue of about $376 million, compared with a prior outlook range of $365 million to $375 million.

Four analysts surveyed by FactSet expect $370.2 million.

The company said it expects full-year operating expenses to be within its guidance range of $304 million to $308 million.

"We anticipate sustained revenue growth and continued advancement of our clinical pipeline in 2026," Pharming Group said.

The company plans to report Q4 and 2025 results March 12.